Published in Lancet on June 26, 2010
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes | NCT02380521
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients | NCT03419624
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 2.59
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab (2013) 1.77
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open (2013) 1.65
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care (2011) 1.61
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther (2011) 1.57
Incretin-based therapies. J Diabetes (2012) 1.48
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol (2011) 1.31
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab (2013) 1.22
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab (2016) 1.15
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res (2011) 1.12
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med (2011) 1.12
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res (2012) 1.06
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care (2012) 1.04
GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab (2012) 1.01
Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev (2013) 1.00
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med (2013) 0.98
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig (2012) 0.98
Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci (2014) 0.97
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol (2015) 0.97
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev (2014) 0.94
Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract (2012) 0.94
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab (2015) 0.94
A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J Control Release (2013) 0.93
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context (2015) 0.93
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc Natl Acad Sci U S A (2013) 0.92
Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care (2015) 0.91
GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud (2011) 0.91
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med (2013) 0.91
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab (2012) 0.91
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes (2015) 0.88
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther (2012) 0.87
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS One (2015) 0.86
Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig (2013) 0.86
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol (2013) 0.86
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. Diabetes Ther (2013) 0.86
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract (2014) 0.85
Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care (2013) 0.84
Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res (2012) 0.84
The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One (2015) 0.84
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol (2013) 0.84
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab (2015) 0.84
Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther (2013) 0.84
The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation. J Diabetes Sci Technol (2012) 0.84
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs. J Diabetes Sci Technol (2016) 0.82
Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab (2016) 0.82
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.81
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. AAPS PharmSciTech (2015) 0.81
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes (2013) 0.80
Individualised incretin-based treatment for type 2 diabetes. Lancet (2010) 0.80
Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Ther (2011) 0.79
Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc (2014) 0.79
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol (2016) 0.79
Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. Diabetes Technol Ther (2011) 0.79
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag (2012) 0.78
Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther (2014) 0.78
A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther (2012) 0.78
Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Prefer Adherence (2013) 0.78
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) (2016) 0.78
Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. J Am Coll Cardiol (2016) 0.77
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Ther Clin Risk Manag (2015) 0.77
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord (2016) 0.77
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian J Endocrinol Metab (2016) 0.77
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf (2012) 0.76
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul) (2016) 0.76
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. Diabetes Metab Syndr Obes (2013) 0.76
Emerging utility of once-weekly exenatide in patients with type 2 diabetes. Diabetes Metab Syndr Obes (2015) 0.76
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes (2014) 0.75
Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c? PLoS One (2016) 0.75
A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol (2017) 0.75
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes (2017) 0.75
Longacting exenatide in diabetes: DURATION-3. Lancet (2010) 0.75
A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy. Cardiovasc Diabetol (2015) 0.75
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab (2016) 0.75
An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method. Diabetes Metab Syndr Obes (2016) 0.75
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab (2017) 0.75
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. Diabetes Metab Syndr Obes (2017) 0.75
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev (2016) 0.75
Exenatide in type 2 diabetes. Lancet (2010) 0.75
Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes. Adv Ther (2014) 0.75
Class of once-weekly diabetes drugs poised for approval. Nat Med (2011) 0.75
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia (2017) 0.75
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab (2017) 0.75
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 3.41
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
The prevalence, anatomical correlates and treatment of sleep-disordered breathing in obese children and adolescents. Sleep Med Rev (2008) 2.33
Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring. Diabetes Care (2006) 2.18
Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism (2006) 2.14
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 2.12
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery (2006) 2.05
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Use of on-line evidence-based resources at the point of care. Fam Med (2003) 1.96
Family medicine patients' use of the Internet for health information: a MetroNet study. J Am Board Fam Med (2006) 1.93
Variants in the FTO gene are associated with common obesity in the Belgian population. Mol Genet Metab (2007) 1.82
Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med (2011) 1.82
Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution. Arch Dis Child (2006) 1.67
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 1.66
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther (2011) 1.57
Prevalence of loss-of-function FTO mutations in lean and obese individuals. Diabetes (2009) 1.54
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol (2011) 1.54
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 1.50
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev (2004) 1.43
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet (2011) 1.33
Correction and use of biomedical literature affected by scientific misconduct. Sci Eng Ethics (2007) 1.24
The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One (2013) 1.22
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract (2008) 1.21
Racial similarities in response to standardized offer of influenza vaccination. A MetroNet study. J Gen Intern Med (2006) 1.20
Obesity and persistent organic pollutants: possible obesogenic effect of organochlorine pesticides and polychlorinated biphenyls. Obesity (Silver Spring) (2010) 1.19
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol (2009) 1.19
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol (2005) 1.19
Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab (2006) 1.16
Effect of long-term whole body vibration training on visceral adipose tissue: a preliminary report. Obes Facts (2010) 1.14
Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol (2005) 1.13
Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care (2011) 1.12
Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes (2011) 1.12
Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract (2005) 1.11
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther (2005) 1.07
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care (2012) 1.04
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord (2011) 1.04
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther (2005) 1.01
Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol (2012) 1.00
Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Diabetes Metab Res Rev (2006) 0.99
Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review. Curr Diabetes Rev (2008) 0.97
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One (2013) 0.97
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism (2009) 0.97
Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. J Clin Invest (2013) 0.96
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia (2013) 0.95
Sleep-disordered breathing and uric acid in overweight and obese children and adolescents. Chest (2007) 0.94
Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol (2012) 0.94
Pharyngitis clinical prediction rules: effect of interobserver agreement: a MetroNet study. J Clin Epidemiol (2004) 0.93
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin (2005) 0.91
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine (2007) 0.91
Efficacy and safety of the weight-loss drug rimonabant. Lancet (2008) 0.91
Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS One (2012) 0.90
The effect of weight loss on sleep-disordered breathing in obese teenagers. Obesity (Silver Spring) (2009) 0.90
The effect of whole body vibration short-term exercises on respiratory gas exchange in overweight and obese women. Phys Sportsmed (2009) 0.89
A review of current evidence with continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol (2008) 0.89
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin (2008) 0.89
Association of the BDNF Val66Met variation with obesity in women. Mol Genet Metab (2008) 0.88
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery (2007) 0.88
Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. Curr Diabetes Rev (2008) 0.88
Dynamics of organohalogenated contaminants in human serum from obese individuals during one year of weight loss treatment. Environ Sci Technol (2013) 0.87
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens (2008) 0.87
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2015) 0.86
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine (2012) 0.86
Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res (2004) 0.86
Patient-clinician agreement on signs and symptoms of 'strep throat': a MetroNet study. Fam Pract (2004) 0.85
Sleep-disordered breathing and C-reactive protein in obese children and adolescents. Sleep Breath (2013) 0.85
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary (2015) 0.85
Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. Metabolism (2013) 0.83
Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device. Diabetes Metab Res Rev (2004) 0.83
Adeno-associated virus-mediated expression of acid sphingomyelinase decreases atherosclerotic lesion formation in apolipoprotein E(-/-) mice. J Gene Med (2011) 0.83
Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol (2010) 0.83
Overweight in adolescents: differences per type of education. Does one size fit all? J Nutr Educ Behav (2008) 0.83
Women's decision making about the use of hormonal and nonhormonal remedies for the menopausal transition. J Obstet Gynecol Neonatal Nurs (2003) 0.83
Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. Value Health (2010) 0.82
Herbal product use and menopause symptom relief in primary care patients: a MetroNet study. J Womens Health (Larchmt) (2003) 0.81
Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs (2009) 0.81
Possible role for ENPP1 polymorphism in obesity but not for INSIG2 and PLIN variants. Endocrine (2009) 0.80
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab (2002) 0.80
Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res (2009) 0.80
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) (2009) 0.80
Coenzyme Q as an antiadipogenic factor. Antioxid Redox Signal (2010) 0.78